预测性和预后性生物标志物在女性下生殖道病理学中的作用：PD-L1、MMR、HER2、p16、p53 及其他。

IF 5.1 2区医学 Q1 PATHOLOGY

Advances In Anatomic Pathology Pub Date : 2025-01-01 Epub Date: 2024-09-16 DOI:10.1097/PAP.0000000000000458

Anne M Mills, Andre Pinto

{"title":"预测性和预后性生物标志物在女性下生殖道病理学中的作用：PD-L1、MMR、HER2、p16、p53 及其他。","authors":"Anne M Mills, Andre Pinto","doi":"10.1097/PAP.0000000000000458","DOIUrl":null,"url":null,"abstract":"Biomarkers play a crucial role in the diagnosis, treatment planning, and prognosis of premalignant and malignant lesions and are increasingly used in neoplasia of the lower female genital tract (LFGT) including the cervix, vagina, and vulva. This review will discuss key biomarkers routinely used in LFGT pathology, including programmed cell death ligand 1 (PD-L1), mismatch repair (MMR), and tumor mutational burden (TMB) testing, which are FDA-approved companion diagnostics for anti-PD-1 checkpoint inhibitors. Recent developments in HER2 testing as a marker for anti-HER2 therapies, and prognostic biomarkers such as p53 in HPV-independent vulvar intraepithelial lesions and carcinomas, are also reviewed.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":" ","pages":"30-43"},"PeriodicalIF":5.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Role of Predictive and Prognostic Biomarkers in Lower Female Genital Tract Pathology: PD-L1, MMR, HER2, p16, p53, and Beyond.\",\"authors\":\"Anne M Mills, Andre Pinto\",\"doi\":\"10.1097/PAP.0000000000000458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biomarkers play a crucial role in the diagnosis, treatment planning, and prognosis of premalignant and malignant lesions and are increasingly used in neoplasia of the lower female genital tract (LFGT) including the cervix, vagina, and vulva. This review will discuss key biomarkers routinely used in LFGT pathology, including programmed cell death ligand 1 (PD-L1), mismatch repair (MMR), and tumor mutational burden (TMB) testing, which are FDA-approved companion diagnostics for anti-PD-1 checkpoint inhibitors. Recent developments in HER2 testing as a marker for anti-HER2 therapies, and prognostic biomarkers such as p53 in HPV-independent vulvar intraepithelial lesions and carcinomas, are also reviewed.\",\"PeriodicalId\":7305,\"journal\":{\"name\":\"Advances In Anatomic Pathology\",\"volume\":\" \",\"pages\":\"30-43\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances In Anatomic Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PAP.0000000000000458\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances In Anatomic Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PAP.0000000000000458","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

生物标志物在癌前病变和恶性病变的诊断、治疗计划和预后判断中起着至关重要的作用，并越来越多地应用于女性下生殖道（LFGT）肿瘤，包括宫颈、阴道和外阴。本综述将讨论LFGT病理学中常规使用的关键生物标记物，包括程序性细胞死亡配体1（PD-L1）、错配修复（MMR）和肿瘤突变负荷（TMB）检测，这些都是FDA批准的抗PD-1检查点抑制剂的辅助诊断方法。此外，还综述了作为抗 HER2 疗法标记物的 HER2 检测以及预后生物标记物（如 HPV 非依赖性外阴上皮内病变和癌中的 p53）的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The Role of Predictive and Prognostic Biomarkers in Lower Female Genital Tract Pathology: PD-L1, MMR, HER2, p16, p53, and Beyond.

Biomarkers play a crucial role in the diagnosis, treatment planning, and prognosis of premalignant and malignant lesions and are increasingly used in neoplasia of the lower female genital tract (LFGT) including the cervix, vagina, and vulva. This review will discuss key biomarkers routinely used in LFGT pathology, including programmed cell death ligand 1 (PD-L1), mismatch repair (MMR), and tumor mutational burden (TMB) testing, which are FDA-approved companion diagnostics for anti-PD-1 checkpoint inhibitors. Recent developments in HER2 testing as a marker for anti-HER2 therapies, and prognostic biomarkers such as p53 in HPV-independent vulvar intraepithelial lesions and carcinomas, are also reviewed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances In Anatomic Pathology 医学-病理学

CiteScore

10.30

自引率

3.00%

发文量

审稿时长

>12 weeks

期刊介绍： Advances in Anatomic Pathology provides targeted coverage of the key developments in anatomic and surgical pathology. It covers subjects ranging from basic morphology to the most advanced molecular biology techniques. The journal selects and efficiently communicates the most important information from recent world literature and offers invaluable assistance in managing the increasing flow of information in pathology.